#China #Shanghai #CAR-T therapy #lymphoma treatment #Jiahui Health

Overcoming Lymphoma: A Journey from Pakistan to Shanghai

In an inspiring tale of resilience and hope, a 36-year-old man from Quetta, Pakistan, embarked on a medical journey that led him to the Jiahui International Cancer Center in Shanghai. His battle against diffuse large B-cell lymphoma (DLBCL) had seen him traverse various treatment methods, only to face the daunting reality of stage IVB cancer with metastasis affecting his lungs, pleura, and bones.

The Fight for Life

Muhammad, a dedicated hospital staff member, had already undergone several cycles of chemotherapy along with a failed bone marrow transplant. The once bright prospect of recovery faded as his cancer progressed, accompanied by severe pain that no local treatment could alleviate. After consultations with local doctors, he learned that no further effective conventional treatments were available. Faced with such grim information, he sought hope through overseas advanced therapy, obtaining approval from Pakistan's national medical board for his treatment abroad.

Choosing the Right Center

Multiple institutions across the globe were evaluated before Muhammad decided on Jiahui, primarily for its efficient consultation and robust support for international patients. The tailored guidance he received throughout the pre-treatment phase significantly influenced his choice. The hope of receiving advanced CAR-T therapy, a cutting-edge treatment method, provided a glimmer of optimism in a dire situation.

Personalized Therapy Plan

Upon arrival at Jiahui, Muhammad was met by Dr. Hao Siguo, the Chief Hematology Consultant, who was instrumental in designing a personalized CAR-T therapy regimen. Knowing that Muhammad’s condition was complex, with a substantial tumor burden, Dr. Hao initiated a bridging therapy combining chemotherapy and localized radiotherapy to diminish the tumor size before the CAR-T cell infusion. This strategy was pivotal in reducing the risks associated with the infusion and enhancing overall treatment efficacy.

Administration of CAR-T Therapy

With vital organ functions stable, the multidisciplinary team at Jiahui proceeded with the personalized therapy as planned. After completing the lymphocyte collection process — the cornerstone of CAR-T therapy — and preparatory treatments to optimize his condition for a safe cell infusion, Muhammad received his customized CAR-T infusion on April 23, 2026.

During the inpatient observation period that followed, he experienced mild cytokine release syndrome but thankfully no severe neurotoxicity. Remarkably, positive clinical improvements manifested swiftly; his severe cancer pain was greatly alleviated, and reliance on opioid medications dropped significantly. Tests conducted before discharge indicated a reduction in the size of tumors and a normalization of critical laboratory indicators.

Comprehensive Support from Jiahui

Throughout his treatment, the international care team at Jiahui offered unwavering support, including professional translation services and nutrition accommodations in the form of halal catering, ensuring his cultural and religious needs were met.

Muhammad expressed his gratitude for the kindness shown to him during his stay in China, noting, "The Chinese people are very cooperative. The doctors, nurses, and staff were very supportive." He was discharged on May 7, 2026, with a tailored plan for continuous follow-up imaging and monitoring upon returning to Pakistan.

A Testament to Hope and Innovation

This case exemplifies the remarkable capabilities of the Jiahui International Cancer Center in delivering efficient CAR-T therapy for patients with refractory lymphoma. It highlights not only the advanced medical options available in Shanghai but also the potential benefits for patients around the world who seek comprehensive cross-border medical services for complex oncological conditions. As Muhammad continues his recovery journey back in Pakistan, his story serves as a beacon of hope for others facing similar battles.